Difference between revisions of "Gardasil"
Jump to navigation
Jump to search
| Line 1: | Line 1: | ||
| − | + | The HPV vaccine protects against some strains of the human papillomavirus (HPV), which are sexually transmitted diseases. In June 2006, the U.S. Food and Drug Administration approved the first HPV vaccine based on observance of elevated antibodies in a few thousand patients who had received the vaccine (including perhaps only a few hundred or less young girls). | |
| − | + | Merck manufactures the HPV vaccine and sells it for $360 ($120 per shot in a three-shot series). Its package insert explains the limitations of the vaccine and describes its testing for safety and efficacy.<ref>http://www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf</ref> | |
| − | + | ---- | |
| − | + | '''Sources:''' <references/> | |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
Revision as of 05:10, February 6, 2007
The HPV vaccine protects against some strains of the human papillomavirus (HPV), which are sexually transmitted diseases. In June 2006, the U.S. Food and Drug Administration approved the first HPV vaccine based on observance of elevated antibodies in a few thousand patients who had received the vaccine (including perhaps only a few hundred or less young girls).
Merck manufactures the HPV vaccine and sells it for $360 ($120 per shot in a three-shot series). Its package insert explains the limitations of the vaccine and describes its testing for safety and efficacy.[1]
Sources: